Syapse’s Post

Interesting paper in Clinical Cancer Research: Circulating tumor DNA enables sensitive detection of actionable gene fusions and rearrangements across cancer types https://lnkd.in/eyH9nK84 In contrast to some prior literature, this study reports detection of a wide variety of rearrangements in ctDNA. The prevalence of driver rearrangements in tissue and LBx was comparable when TF ≥1%. LBx presents a viable alternative when TBx is not available, and there may be less value in confirmatory testing when TF is sufficient.

🔬 Major Breakthrough Alert! 🔬 Mayo Clinic's latest research unveils new gene markers that could revolutionize the way we detect Lynch syndrome-associated colorectal cancer. 🙌 Early detection is crucial, and this discovery brings us one step closer to more effective screening and treatment. 💪 Read the full story: https://lnkd.in/dF3kpB_V Let's spread the word and raise awareness about this game-changing development in cancer research! 🎗️ #CancerResearch #LynchSyndrome #ColorectalCancer #MedicalBreakthrough #MayoClinic #Researchanddevelopment #SCLAManagement

Do women with dense breast tissue face a higher likelihood of developing breast cancer, and experience reduced early detection capabilities through mammography? In 2024, women in the United States will be notified about their breast density status as part of their mammogram reports. Understand your patient’s breast cancer risk in the context of their breast density status: https://lnkd.in/guN6Eedz #bcsm #KnowYourRisk #mammography

Pancreatic cancer develops when uncontrolled cell growth begins in a part of the pancreas. Early-stage pancreatic tumors don’t show up on imaging tests. Signs and symptoms of pancreatic cancer include jaundice, pain, and weight loss. Molecular genetic testing can help in identification of the various risk factors that increases the chance of pancreatic cancer. #pancreaticcancerawareness #signsandsymptoms #EarlyDetectionMatters #moleculargenetictesting

Findings from the Phase III PARADIGM trial published in Nature Medicine on February 14, 2024, shed light on biomarker-driven treatment for metastatic colorectal cancer (mCRC). The trial demonstrated that patients with RAS wild-type mCRC and left-sided tumors showed longer overall survival with panitumumab plus mFOLFOX6. For this prespecified analysis, we designed and validated a custom CRC ctDNA assay using a comprehensive panel of gene alterations associated with resistance to anti-EGFR therapy. These exploratory biomarker results underscore the potential of ctDNA in guiding optimal treatment decisions for mCRC patients in the frontline setting.

Findings from the Phase III PARADIGM trial published in Nature Medicine on February 14, 2024, shed light on biomarker-driven treatment for metastatic colorectal cancer (mCRC). The trial demonstrated that patients with RAS wild-type mCRC and left-sided tumors showed longer overall survival with panitumumab plus mFOLFOX6. For this prespecified analysis, we designed and validated a custom CRC ctDNA assay using a comprehensive panel of gene alterations associated with resistance to anti-EGFR therapy. These exploratory biomarker results underscore the potential of ctDNA in guiding optimal treatment decisions for mCRC patients in the frontline setting.

Findings from the Phase III PARADIGM trial published in Nature Medicine on February 14, 2024, shed light on biomarker-driven treatment for metastatic colorectal cancer (mCRC). The trial demonstrated that patients with RAS wild-type mCRC and left-sided tumors showed longer overall survival with panitumumab plus mFOLFOX6. For this prespecified analysis, we designed and validated a custom CRC ctDNA assay using a comprehensive panel of gene alterations associated with resistance to anti-EGFR therapy. These exploratory biomarker results underscore the potential of ctDNA in guiding optimal treatment decisions for mCRC patients in the frontline setting.

Findings from the Phase III PARADIGM trial published in Nature Medicine on February 14, 2024, shed light on biomarker-driven treatment for metastatic colorectal cancer (mCRC). The trial demonstrated that patients with RAS wild-type mCRC and left-sided tumors showed longer overall survival with panitumumab plus mFOLFOX6. For this prespecified analysis, we designed and validated a custom CRC ctDNA assay using a comprehensive panel of gene alterations associated with resistance to anti-EGFR therapy. These exploratory biomarker results underscore the potential of ctDNA in guiding optimal treatment decisions for mCRC patients in the frontline setting.

Findings from the Phase III PARADIGM trial published in Nature Medicine on February 14, 2024, shed light on biomarker-driven treatment for metastatic colorectal cancer (mCRC). The trial demonstrated that patients with RAS wild-type mCRC and left-sided tumors showed longer overall survival with panitumumab plus mFOLFOX6. For this prespecified analysis, we designed and validated a custom CRC ctDNA assay using a comprehensive panel of gene alterations associated with resistance to anti-EGFR therapy. These exploratory biomarker results underscore the potential of ctDNA in guiding optimal treatment decisions for mCRC patients in the frontline setting.

Findings from the Phase III PARADIGM trial published in Nature Medicine on February 14, 2024, shed light on biomarker-driven treatment for metastatic colorectal cancer (mCRC). The trial demonstrated that patients with RAS wild-type mCRC and left-sided tumors showed longer overall survival with panitumumab plus mFOLFOX6. For this prespecified analysis, we designed and validated a custom CRC ctDNA assay using a comprehensive panel of gene alterations associated with resistance to anti-EGFR therapy. These exploratory biomarker results underscore the potential of ctDNA in guiding optimal treatment decisions for mCRC patients in the frontline setting.